Home Nucleus Medical Devices U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032

U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032

Overview

The U.S. Pharmacogenetics Testing in Psychiatry-Depression Market is expected to reach a 1,743.68 USD Billion by 2032 and is projected to grow at a CAGR of 13.37% from 2025 to 2032.

Revenue, 2024 (USD Billion)
807.70
Forecast, 2032 (USD Billion)
1,743.68
CAGR, 2024 - 2032
13.37%
Report Coverage
U.S.

U.S. Pharmacogenetics Testing in Psychiatry-Depression Market 2018-2032 USD Billion

U.S. Pharmacogenetics Testing in Psychiatry-Depression Market, Key Findings (2025-2032)

Market Growth and Projections:

  • Market Size (2024): 807.70 USD Billion
  • Projected Market Size (2032): 1,743.68 USD Billion
  • CAGR (2025-2032): 13.37%

Key Findings of U.S. Pharmacogenetics Testing in Psychiatry-Depression Market

  • The U.S. Pharmacogenetics Testing in Psychiatry-Depression Market was valued at 807.70 USD Billion in 2024.
  • The U.S. Pharmacogenetics Testing in Psychiatry-Depression Market is likely to grow at a CAGR of 13.37% during the forecast period of 2024 to 2032.
  • In 2024, the Largest segment Whole Genome Sequencing in Test Segment accounted for the largest share of the market with a revenue of 859.86 USD Billion
  • The fastest growing segment CYP2C19 in Gene Segment grew Fastest with a CAGR of 17.67% during the forecast period from 2024 to 2032.

U.S. Pharmacogenetics Testing in Psychiatry-Depression Market Scope

U.S. Pharmacogenetics Testing in Psychiatry-Depression Market Segmentation & Scope
End User
  • Others
  • Academic And Research Institutes
  • Diagnostics Laboratories
  • Hospital and Clinics
Distribution Channel
  • Others
  • Hospital Pharmacy
  • Third Party Distribution
  • Direct Tender
Gene
  • COMT
  • MTHFR
  • SLC6A4
  • CYP3A4
  • HLA-A
  • HTR2A/C
  • Others
  • HLA-B
  • CYP2D6
  • CYP2C9 AND VKORC1
  • CYP2C19
Patient
  • Child
  • Geriatric
  • Adult
Type
  • Psychotic Disorders
  • Eating Disorders
  • Bipolar Disorders
  • Mood Disorders
  • Depression
  • Anxiety
Product
  • Software and Services
  • Instruments
  • Consumables
Test
  • Chromosomal Array Based Tests
  • Whole Genome Sequencing

U.S. Pharmacogenetics Testing in Psychiatry-Depression Market Data Coverage Insights

Study Period 2024-2032
Base Year 2022
Unit Revenue in USD Billion
Market Value in 2024 807.70 USD Billion
Market Value in 2032 1,743.68 USD Billion
CAGR (2025-2032) 13.37%
Historic Data 2016-2023
Market Segments Covered End User,Distribution Channel, Gene,Patient,Type,Product,Test

Regional Insights:

  • Leading Market (2024-2032): U.S., leading in terms of revenue 807.70 USD Billion in 2024
    • Key Country: U.S., leading in terms of revenue with value of 807.70 USD Billion in 2024.

Segments and Scope

  • U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By End User
    • Academic And Research Institutes is the largest segment in U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 390.73 USD Billion in the year 2024.
    • Academic And Research Institutes is the Fastest growing segment in U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 14.83 % in forecast period 2025-2032.
  • U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Distribution Channel
    • Direct Tender is the largest segment in U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 398.00 USD Billion in the year 2024.
    • Direct Tender is the Fastest growing segment in U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 14.62 % in forecast period 2025-2032.
  • U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Gene
    • CYP2C19 is the largest segment in U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 229.52 USD Billion in the year 2024.
    • CYP2C19 is the Fastest growing segment in U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 17.67 % in forecast period 2025-2032.
  • U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Patient
    • Adult is the largest segment in U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 483.76 USD Billion in the year 2024.
    • Adult is the Fastest growing segment in U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 14.54 % in forecast period 2025-2032.
  • U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Type
    • Anxiety is the largest segment in U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 332.76 USD Billion in the year 2024.
    • Anxiety is the Fastest growing segment in U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 15.89 % in forecast period 2025-2032.
  • U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Product
    • Consumables is the largest segment in U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 412.08 USD Billion in the year 2024.
    • Consumables is the Fastest growing segment in U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 15.19 % in forecast period 2025-2032.
  • U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Test
    • Whole Genome Sequencing is the largest segment in U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 859.86 USD Billion in the year 2024.
    • Whole Genome Sequencing is the Fastest growing segment in U.S. Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 16.23 % in forecast period 2025-2032.

U.S. Pharmacogenetics Testing in Psychiatry-Depression Market Company Share Analysis

 
Company Name Company Share Analysis
Myriad Genetics, Inc.
Illumina, Inc.
Thermo Fisher Scientific Inc.
Qiagen
Sonic Healthcare Limited
U.S. Pharmacogenetics Testing in Psychiatry-Depression Market Company Share Analysis

U.S. Pharmacogenetics Testing in Psychiatry-Depression Market Geographical Sales Distribution, 2018-2032 USD Billion

U.S. Pharmacogenetics Testing in Psychiatry-Depression Market Geographical Sales Distribution, 2018-2032 USD Billion

U.S. Pharmacogenetics Testing in Psychiatry-Depression Market Company Profiling

U.S. Pharmacogenetics Testing in Psychiatry-Depression Market Company Profiling

Industry Related Reports

South America Hospital Furniture Market
Middle East & Africa Hospital Furniture Market
North America Hospital Furniture Market
Europe Hospital Furniture Market
Asia-Pacific Hospital Furniture Market
Argentina Hospital Furniture Market
Australia Hospital Furniture Market
Belgium Hospital Furniture Market
Brazil Hospital Furniture Market
Canada Hospital Furniture Market
Frequently Asked Questions
The U.S. Pharmacogenetics Testing in Psychiatry-Depression Market is segmented based on Segmentation End User,Distribution Channel, Gene,Patient,Type,Product,Test.
U.S. Pharmacogenetics Testing in Psychiatry-Depression Market was valued at USD 807.70(Revenue in USD Billion) in 2022.
U.S. Pharmacogenetics Testing in Psychiatry-Depression Market is projected to grow at a CAGR of 13.37% during the forecast period of 2024 to 2032.
The Whole Genome Sequencing segment is expected to dominate the U.S. Pharmacogenetics Testing in Psychiatry-Depression Market, holding a largest market share of 859.86 USD Billion in 2024

Coming Soon....

U.S. Pharmacogenetics Testing in Psychiatry-Depression Market Scope

U.S. Pharmacogenetics Testing in Psychiatry-Depression Market Segmentation & Scope
End User
  • Others
  • Academic And Research Institutes
  • Diagnostics Laboratories
  • Hospital and Clinics
Distribution Channel
  • Others
  • Hospital Pharmacy
  • Third Party Distribution
  • Direct Tender
Gene
  • COMT
  • MTHFR
  • SLC6A4
  • CYP3A4
  • HLA-A
  • HTR2A/C
  • Others
  • HLA-B
  • CYP2D6
  • CYP2C9 AND VKORC1
  • CYP2C19
Patient
  • Child
  • Geriatric
  • Adult
Type
  • Psychotic Disorders
  • Eating Disorders
  • Bipolar Disorders
  • Mood Disorders
  • Depression
  • Anxiety
Product
  • Software and Services
  • Instruments
  • Consumables
Test
  • Chromosomal Array Based Tests
  • Whole Genome Sequencing
Frequently Asked Questions
The U.S. Pharmacogenetics Testing in Psychiatry-Depression Market is segmented based on Segmentation End User,Distribution Channel, Gene,Patient,Type,Product,Test.
U.S. Pharmacogenetics Testing in Psychiatry-Depression Market was valued at USD 807.70(Revenue in USD Billion) in 2022.
U.S. Pharmacogenetics Testing in Psychiatry-Depression Market is projected to grow at a CAGR of 13.37% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Pharmacogenetics Testing in Psychiatry-Depression Market for final year is USD 1,743.68 (USD Billion).

U.S. Pharmacogenetics Testing in Psychiatry-Depression Market Company Profiling

U.S. Pharmacogenetics Testing in Psychiatry-Depression Market Company Profiling
Frequently Asked Questions
The U.S. Pharmacogenetics Testing in Psychiatry-Depression Market is segmented based on Segmentation End User,Distribution Channel, Gene,Patient,Type,Product,Test.
U.S. Pharmacogenetics Testing in Psychiatry-Depression Market was valued at USD 807.70(Revenue in USD Billion) in 2022.
U.S. Pharmacogenetics Testing in Psychiatry-Depression Market is projected to grow at a CAGR of 13.37% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Pharmacogenetics Testing in Psychiatry-Depression Market for final year is USD 1,743.68 (USD Billion).

Related Markets

HAVE A QUESTION?

Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.